Aim of the study was to prospectively evaluate efficacy, safety and impact on life expectancy of levetiracetam, oxcarbazepine and topiramate monotherapy in 48 patients with brain metastases. Eighteen patients dropped out, therefore we followed 30 patients. Mean duration of follow up was 6.1 months. At final follow up, 19 patients were seizure-free, while the remaining had a significant reductions of their seizures. There was no difference among each antiepileptic treatment group, we again observed a significant improvement of seizure frequency. Based on Karnofsky Performance Status, age, numbers of cerebral metastases and median of months of survival (7 months) the classification of the total number of our patients can be likened to Class I of prognostic factors of Radiation Therapy Oncology Group (ROTG). There were no significant differences in median survival time between the three groups of patients. The median survival time of our patients treated with levetiracetam, oxcarbazepine and topiramate remained similar to Class I ROTG patients. Our data indicate that levetiracetam, oxcarbazepine and topiramate can be utilized with good tolerability and efficacy over time and without compromising life expectancy in patients with brain metastases, making these antiepileptics a good choice for these patients.
|Translated title of the contribution||Antiepileptic drugs in cerebral metastases: Efficacy, tolerability and impact on life expectancy|
|Number of pages||4|
|Journal||Bollettino - Lega Italiana contro l'Epilessia|
|Publication status||Published - Apr 2010|
ASJC Scopus subject areas
- Clinical Neurology